Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 94.72% year-over-year to $1.7 million; the TTM figure through Sep 2025 stood at $1.7 million (down 94.72% YoY), while the FY2024 annual figure was $35.4 million, down 36.12% from the prior year.
• Non-Current Deffered Revenue was $1.7 million for Q3 2025 at Assembly Biosciences, down from $13.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $55.4 million in Q4 2023 to a low of $1.7 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $13.9 million across 5 years, with a median of $2.7 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deffered Revenue jumped 1926.31% in 2023, then plunged 94.72% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then surged by 1926.31% to $55.4 million in 2023, then slumped by 36.12% to $35.4 million in 2024, then plunged by 95.15% to $1.7 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $1.7 million (Q3 2025), $13.0 million (Q2 2025), and $22.8 million (Q1 2025), per Business Quant data.